News

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


ImmunotherapyWebsite Images Featured 20

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has proved to be effective. We show how the same approach of CAR T cells specific for CD30 (CD30.CAR-Ts) can be used to treat Hodgkin lymphoma (HL).

Visit website
ImmunotherapyWebsite Nurses Patients 24

The Society for Immunotherapy of Cancer (SITC) consensus statement on immunother...

The SITC convened an expert panel,to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. 

Visit website
immunotherapywebsite image Edication resized

Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic l...

Chimeric antigen receptor T (CART) cells targeting CD19 have shown promising results in the treatment of chronic lymphocytic leukemia (CLL). However, efficacy seems to be inferior compared to diffuse large B‐cell lymphoma or acute lymphoblastic leukemia. Impaired T‐cell fitness of CLL patients may be involved in treatment failure.

Visit website
ImmunotherapyWebsite Images Featured 1

Harnessing Stem Cell–Like T Cells to Better Fight Cancer

Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.

Visit website
IJC

Cost of decentralized CAR T‐cell production in an academic nonprofit setting

  Jun 23 2020 Tagged CAR-T

Decentralized T‐cell production might be a less costly and more efficient alternative to the current centralized production mode that requires a high acquisition cost.

Visit website
ImmunotherapyWebsite Nurses Patients 20

Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine ...

This report describes a case of relapsed/refractory ETP-ALL that responded to the combination of venetoclax and nelarabine, when administered as fourth line therapy. 

Visit website
ImmunotherapyWebsite Nurses Patients 21

The Emerging Role of Convalescent Plasma in the Treatment of COVID-19

A detailed overview of randomized as well non-randomized trials of treatment with convalescent plasma, which have been registered worldwide, is provided in this review. 

Visit website
ImmunotherapyWebsite Nurses Patients 22

Allogeneic Hematopoietic Cell Transplantation in Patients With Aplastic Anemia a...

Findings in this report are in line with important important findings of recent studies on eculizumab providing a control population of AA patients with and without PNH clones

Visit website
Imi1

The promise of CAR-T cell therapy

  Feb 18 2020 Tagged CAR-T

Innovative Medicine Initiative (IMI) is a EU public-private partnership funding health research and innovation. Complex therapies like CAR-T cells pose questions no drug developer can answer on thei own.

Visit website
news medical logo2

Death receptor pathway drives resistance to CAR T-cell therapy

Some cancer cells refuse to die, even in the face of powerful cellular immunotherapies like CAR T-cell therapy, and new research from the Abramson Cancer Center of the University of Pennsylvania is shedding light on why. Read the full article here

Visit website